A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies’ partner with CDMOs to outsource drug development and drug manufacturing.
Full-service CDMOs can take on every aspect of drug development and manufacturing, and they also work with clients looking to outsource certain components of their process. It all depends on what each client needs.
When partnering with a full-service CDMO, a pharmaceutical company can begin with little more than a concept and be guided all the way from pre-formulation and formulation development, through clinical trials and commercial production.
- Asymchem Group
Asymchem’s solutions range from early clinical stage to commercial stage, including R&D and cGMP production of advanced intermediates, APIs, formulations, as well as clinical research services. Through strategic partnerships and calculated business growth, they have built an integrated service ecosystem.
They have strong growth plans for 2021 and plan to significantly increase their headcount with specialised talent and capabilities as an organisation. Furthermore, they have exciting plans to be announced that will further establish their US presence within the market.
Solvias is a world leader in contract research, development, and manufacturing with headquarters in Kaiseraugst near Basel, Switzerland. They provide integrated analytical services and solutions to the pharmaceutical, biotech and medical device industries. Their comprehensive analytical testing portfolio integrates a broad range of capabilities spanning all stages of drug discovery, development, and commercial release for better and safer products. Solvias also offers one of the largest proprietary ligand portfolios for catalytic transformations and a suite of related custom synthesis/manufacturing and catalysis technology services.
Solvias has recently acquired Chemic Laboratories, based in Canton, MA. The acquisition provides Solvias with a strong presence in the U.S. and highly complementary lab testing capabilities. Exciting to see how this will help progress their goals of building Solvias into a global leader and leading competitor of the industry.
Cambrex is the small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. They offer a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and highly potent APIs. In addition, Cambrex can support conventional dosage forms including oral solids, semi-solids and liquids and has the expertise to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.
They are one of the major players within the small molecule space however, that does not mean they are not one to watch. They always have exciting plans for growth with their team of experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.
4. TriRx Pharmaceutical Services
TriRx Pharmaceutical Services is a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical market. Headquartered approximately 50 miles outside of New York City in Norwalk, Connecticut, we operate facilities providing state-of-the-art laboratory, manufacturing, packaging and warehousing capabilities.
Founded and led by a team of pharmaceutical industry executives who have served as both contract service providers and customers, TriRx has a profound and multifaceted understanding of customer needs.
The CDMO is to purchase Elanco Animal Health’s sites in Shawnee, KS and Speke, UK including planned transfer of 600 employees. The companies have also entered into a long-term supply agreement for the facilities to continue to manufacture existing Elanco products. Definitely one to watch with their efforts of long-term competitiveness.
Yposkesi is one of the largest Contract Development & Manufacturing Organizations in Europe for gene therapy viral vector manufacturing. A spin-off from the world-class gene therapy pioneer Genethon, Yposkesi capitalizes on more than 20 years’ expertise in biotherapeutic research.
Yposkesi have just launched project SKY, the construction of a second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). They are backed by an investment of approximately $71 million in the new 50,000 ft² site, making it one of the largest ATMP facilities in Europe. Project SKY will create approximately 80 new jobs by 2023. With this new state-of-the-art facility, designed for European and American GMP compliance, Yposkesi will double its production surface to 100,000 ft². This new resource addresses the shortage in manufacturing capacity for drug developers seeking to advance clinical trials and commercialize new therapeutic drugs.